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Abstract
Background: Chronic Spinal Cord injury is a common, severe, and medically untreatable disease. Since the
functional outcomes of acute and experimental chronic spinal cord injury have been shown to improve with stem
cell therapy, a case study was conducted to test if the application of stem cell also regenerates chronic SCI
dysfunction. Transplantation of foetal bone marrow stem cells was applied in seven dogs with chronic spinal cord
injury. Magnetic resonance images and assessments of symptoms according to the Olby scale were used to
diagnose the severity of injury.
Result: All dogs improved locomotor and sensory function when examined 90 days after surgery, and showed
increased movement of the hind limbs, and were able to stand upright, as well as to take small steps. Tail tone was
observed in seven dogs, pain reflexes and defecation return were observed in five dogs.
Conclusion: The transplantation of bone marrow stem may be a promising, reliable and safe treatment for chronic
spinal cord injury.
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Background
Spinal Cord injury (SCI) is a disease with devastating ef-
fect on dogs, including paresis or paralysis and/or urin-
ary and faecal incontinence. Chronic SCI is regarded as
a medically untreatable condition and there is no effect-
ive treatment [1-3]. Spinal cord lesions are commonly
reported in veterinary medicine, especially in dogs,
where they usually occur in association with traumas
that are induced by prolapsed intervertebral discs or ex-
ogenous sources such as motor vehicle accidents [4,5,1].
In humans, between 3 and 5 people per every 100,000
are affected with SCI [6]. Clinical signs in dogs are simi-
lar to those encountered in human patients, and dogs
that suffer from severe SCI have the same poor progno-
sis for neurological recovery as their human counter-
parts [7]. The severity of the neurological signs are
graded as follows: grade I (only spinal hyperaesthesia),
grade II (ambulatory paraperesis, ataxia, proprioceptive
deficits), grade III (non-ambulatory paraparesis), grade
IV (paraplegia with nociception), and grade V (paraple-
gia with loss of nociception) [8]. Likewise, a scale of 14
points is used to assess the severity of the disease [9].
Diagnostic imaging has become increasingly important
for assessing the prognosis and determining treatment
decisions with intervertebral disc extrusion [8,10-12].
For dogs, the temporal aspects of the onset and duration
of clinical signs after intervertebral disc herniation have
been used as prognostic indicators [1], suggesting that
clinical assessment is essential after SCI [12].
Treatments with stem cells have been performed in
animal and human SCI models, with promising results
[3,13-16]. In particular, transplantation of stem cells has
been shown to improve the functional outcome of experi-
mental SCI in rats [17-19]. Pre-clinical reports indicate
that the transplantation of bone marrow mesenchymal
stromal cells is encouraging in acute, SCI-simulating
models, including monkeys [20], humans [21] and dogs
[22,23]. The aim of the current pilot project is to evaluate
if transplants of foetal canine bone marrow derived stem
cells into spinal cord lesions improved the regeneration
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and spinal cord function in dogs with severe, chronic
spinal cord lesions.
Results
On the day following surgery, the animals did not present
with any adverse symptoms. There was no formation of
local oedema, seroma, or other complications. No feeding
issues or associated loss of weight was noted during the
investigative period. Sutures were removed after 10 days
without problems.
MRI did not show major differences after the treat-
ment (Figure 1). All animals that were considered for
statistical analysis showed significant improvement of
the Olby scales after stem cell transplantation (Table 1,
Figure 2). They also showed increased movement of the
hind limbs on both treadmills. Animals 3, 4, 6 and 7
were able to support their own weight and to make
small, uncoordinated steps and returned tail tone, super-
ficial and deep pain reflexes as well as defaecation
(Table 1). In detail, Animal 1 suffered from a flaccid par-
alysis without significant joint contracture that became
slightly better after surgery, including movements of the
hind limbs and improved muscle contraction, indicating
a reactivation of the nervous pathways. Animal 2 showed
Figure 1 MRI of dogs thoracolumbar segment. In (A) the pre treatment the animals showed severe extradural compressive myelopathy
ventrolateral between T11-T12 and disc protrusion at L3-L4, disc degeneration and spondylosis multifocal in thoracic and lumbar spine. In (B)
after treatment the animal showed the same diagnosis at MRI without regression or progression of the previous reported. In (C) homogeneous
hyperintensity maintained between T9-L2, extradural compressive myelopathy, mild to moderate between T12-T13, previous surgical procedure
between T11-T13, with secondary muscle atrophy, disc dehydration multifocal in thoracolumbar spine were observed. In (D) after the treatment
the same alterations were observed in the MRI. In (E) myelopathy extradural compressive between T9-T120 and T13-L1, with the presence of
secondary siringohidromielia. In (F) after treatment probable thoracolumbar muscular atrophy with presence of siringohidromielia between
T12-L1 and L3, and severe at T13-L1, multifocal disc dehydration in thoracolumbar spine.
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sharp muscle spasm that compromised the joints of the
hind limbs. After surgery, the muscles recovered, in
addition to an increased range of motion (Table 1). Ani-
mal 3 had little muscle contracture before therapy, but
showed improved movement of the hind limbs in the
aquatic treadmill afterwards. The animal was able to
hold its body weight and to protrude the tail voluntarily
(Table 1). Animal 4 was the only one that was affected by
trauma. Before treatment it suffered from urinary incon-
tinence and could not stand its body. After treatment, it
was able to take several steps and spontaneous voiding
returned. Animal 5 had a bilateral patella dislocation, in
Table 1 Group of animals showing height of the lesion by MRI and data relating to assessments of physical therapy
animals, according to Olby scale before and after the surgical procedure and injection of stem cells
Animal Age-years Breed Diagnosis Lesion Moment Olby scale
1 6 Teckel
Intervertebral
disc extrusion
T13-L1
Pre –
treatment
0 Absence of movement of the hind limbs without feeling deep pain.
Pos –
treatment
3
Minimum protraction (movement of a joint) without dislocation of the pelvic
limb weight.
2 8 Teckel
Intervertebral
disc extrusion
T13-L3
Pre –
treatment
0 Absence of movement of the hind limbs without feeling deep pain.
Pos –
treatment
3
Minimum protraction (movement of a joint) without dislocation of the pelvic
limb weight.
3 6
Lhasa
Apso
Intervertebral
disc extrusion
T11-12
Pre –
treatment
4
Protraction of the hind limbs without displacement in a joint weight of at least
50% of the time.
Pos –
treatment
9
Protraction of the hindlimbs with weight shift in 100% of the time with reduced
strength of hindlimbs. More than 90% error when walking (eg: Crossing pelvic
limbs, shuffling walk, stay on station with the backs of the feet, tripping).
4 2 Mongrel Trauma T10-11
Pre –
treatment
6 Protação hind limb with a displacement of less than 10 weight% of the time.
Pos –
treatment
10
Protraction of the hindlimbs with weight shift in 100% of the time with reduced
strength of hindlimbs.
6 8 Poodle
Intervertebral
disc extrusion
L1-L4
Pre –
treatment
7 Protaction hind limb with a displacement of from 10 to 50 weight% of the time.
Pos –
treatment
10
Protaction of hindlimbs with weight shift in 100% of the time with reduced
strength of hindlimbs.
7 10 Teckel
Intervertebral
disc extrusion
T11-12
Pre –
treatment
3
Minimum protraction (movement of a joint) without dislocation of the pelvic
limb weight.
Pos –
treatment
9
Protraction of the hindlimbs with weight shift in 100% of the time with reduced
strength of hindlimbs mm. More than 90% error when walking (eg: Crossing
pelvic limbs, walking crossing feet remain on station with the backs of the feet,
tripping).
Figure 2 Evolution of the animals according to the scale of Olby [9].
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addition to the spinal lesion, resulting in high muscle con-
traction that became much better after surgery. However,
one knee was not stable and required further surgery dur-
ing the investigated period, and a final assessment of the
Olby score was not possible and the animal was not in-
cluded within the statistical analysis. The animal 6 showed
aggressive behavior and the postoperative evaluation of
superficial and deep pain sensation and panniculus reflex
were performed with the aid of a forceps. In this case and
for Animal 7, a significant improvement in walking and
the return of voluntary movement of the tail was observed
(Table 1). Additional file 1: Videos S1 and S2 were pro-
vided to show the evolution of the one animal treated after
30, 60 and 90 days after treatment.
Discussion
We showed in the current case study that adult dogs with
chronic SCI could be successfully treated with the trans-
plantation of foetal canine bone marrow stem cells. Exam-
ined 90 days after surgery, all animals had increased
locomotor and sensory functions according to the Olby
scale, without health complications or decline in the
neurologic status. The patients received stem cell treat-
ment, but also underwent physical therapy, so it is hard to
determine the exact cause of any improvements. It should
be given thought, however, that many patients with chronic
SCIs do not recover strength so many time post injury with
physical therapy alone [24]. The data suggested that trans-
planted stem cells may lead to a functional recovery of SCI,
similar to what was reported for acute lesions in dogs [22].
Also, it was reported in dogs, indicated by higher values of
the Texas SCI scale after the transplantation of bone mar-
row stem cells [23]. In others studies recovery of motor
and sensory functions 53 days after initial cell transplant-
ation and the ability to stand after 79 days was reported
[25]. The observed improvements in dogs are similar to re-
ports on humans with acute SCI [21]. In addition to the
applications for SCI regeneration, bone marrow stem cells
have broad therapeutic significance. They have been used
as donor cells for haematologic diseases in animal models
[26], or to treat cardiovascular diseases and cancer in
humans [27]. Also, transplanted bone marrow stem cells
improve neurologic disorders in models of central nervous
system injury by generating neural cells or myelin-
producing cells [28]. Donor cells from male humans have
been shown to rebuild neurons in the brains of female re-
cipients [29]. In general, bone marrow stem cells differenti-
ate into a variety of non-hematopoietic cell lineages, e.g.
muscle, skin, liver, lung, cardiac myocytes, endothelial and
neuronal cells [30,31]. For stem cell therapy, the use of
bone marrow-derived stem cells cause minor problems in
regard to immunological rejections, graft-versus-host reac-
tions or carcinogenesis compared to other embryonic or
adult stem cells [32,33].
Conclusion
In addition to the former therapies, our case study indi-
cates that foetal bone marrow stem cells represent a
promising treatment for chronic SCI in canine patients,
however others stem cell sources can also be considered
to use for treatment, suggesting that clinical trials with
more animals are needed.
Methods
Selection of animals and preoperative procedures
Seven dogs with chronic SCI, from different private veter-
inary clinics in São Paulo, were used (Table 1). The selected
animals presented with paralysis, a lack of conscious pro-
prioception, the absence of deep pain perception with pres-
ence of the withdrawal reflex in the hind limbs, assessed
according to the Olby scale (see below), and diagnosis of
spinal cord compression of thoracolumbar intervertebral
discs between segments T10-L3 after magnetic resonance
imaging (MRI). The absence of deep pain perception for
more than 60 days was used as a diagnostic tool for
chronic injury. The animals did not show any positive re-
sponse to former treatments such as medication, physio-
therapy or acupuncture. Conventional examinations (blood
count, biochemistry, urinalysis, stool analysis and electro-
cardiogram) were performed, indicating normal values.
MRI (Vet-MR Grande-Esaot) was performed to determine
the precise location of the lesion. The owners signed an in-
formed consent, making them aware of all procedures and
risks associated with the surgery and cell transplantation.
The project was approved by the Ethical committee of the
University of Sao Paulo (Nr. 2063/2010).
Surgery and cell transplantation
Prior to anesthesia, the animals were injected with
0.05 mg/kg acepram (acepromazine®1) associated with
4 mg/kg dolosal (Meperidine®2), both intramuscularly.
After 15 minutes anaesthesia was induced with 5 mg/kg
propofol (Propovan®3 - Cristália) intravenously and main-
tained by inhalational anaesthesia with isoflurane (Isofor-
ine®4 - Cristália). During surgery the animals underwent
dorsolateral hemilaminectomy in the injured spinal cord.
The incision was made lateral to the midline and dorsal to
the lesion. After incision of the skin and muscles, the
fascia was incised lumbodorsal alongside the correspond-
ing spinous processes of the vertebrae, and, with the aid of
a periosteum elevator, the spinal processes were isolated.
By exposing the dorsal surface of the articular process, a
window was opened to provide access to the spinal canal.
After which, the medullary mass was compressed and
damaged tissue was removed. After durotomia, intrame-
dullary injection of 1×106 of stem cells derived from foetal
canine bone marrow [31] was completed cranial to the
injury, at the focal point of the lesion, and caudal to the
lesion. The postoperative therapy consisted of 30 mg/kg
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Kefazol ® (cefazolin sodium) 30 mg/kg, 0.1 mg/kg meloxi-
cam (Generic Biosintética) and 2 mg/kg Tramal ® (trama-
dol hydrochloride) for seven days.
Postoperative examinations
Seven days after surgery, the animals were trained on
aquatic and dry treadmills. To observe possible improve-
ment, each animal was filmed in different positions 30 and
60 days after surgery (data not shown) as well as after
90 days. The dogs were scored using the Olby scale of 14
points by three veterinary physiotherapists not involved in
the experiments. Dogs were considered to be able to sup-
port their own weight when they maintained their body
for at least four footsteps. The reflexes of superficial and
deep pain were evaluated with the help of tweezers. Statis-
tical analyses were performed using the PRISM 4.0 statis-
tical software package (GraphPad, Inc., San Diego, CA).
Significance for all analyses was set at P-values of 0.05.
Additional file
Additional file 1: Videos S1 and S2. Progressive response of the
animal during the treatment between the analysis performed.
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